Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors

Inclusion Criteria:

* 1 Subjects with advanced malignant tumors clearly diagnosed by pathology and / or cytology, lack of conventional effective treatment methods, failure or relapse after treatment.
* 2 18-75 years old; Eastern Cooperative Oncology Group (ECOG) physical status: 0-1; at least 3 months expected survival period.
* 3 The function of main organs is normal.
* 4 Subjects must need to adopt effective methods of contraception.
* 5 Subjects voluntarily joined the study, signed informed consent form, and with good compliance.

Exclusion Criteria:

* 1 Patients has had or is currently having other malignant tumors within 3 years. The following two conditions can be included in the group: other malignant tumors treated with a single operation to achieved R0 resection without recurrence and metastasis. Cured cervical carcinoma in situ, non-melanoma skin cancer, nasopharyngeal carcinoma and superficial bladder tumors \[Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)\].
* 2 The toxicity of previous antitumor treatment is not recovered to ≤ grade 1 (Common Terminology Criteria for Adverse Events (CTCAE) 5.0).
* 3 Received major surgical treatment, open biopsy or obvious traumatic injury within 28 days before treatment.
* 4 Subjects had an arteriovenous thrombosis event within 6 months.
* 5 Subjects occurred Evans syndrome within 3 months.
* 6 History of drug abuse, alcohol or drug abuse or mental disorder.
* 7 Subjects who suffered from Active tuberculosis within 1 year.
* 8 The subjects had any history of bleeding or coagulopathy.
* 9 Cirrhosis, active hepatitis.
* 10 The subjects was diagnosed with renal failure and required hemodialysis or peritoneal dialysis.
* 11 History of immunodeficiency, including positive human immunodeficiency virus (HIV) test or other acquired, congenital immunodeficiency disease, or history of organ transplantation.
* 12 Subjects who have epilepsy and require treatment.
* 13 Received the treatment of proprietary Chinese medicines with anti-tumor indications clearly stated in the National Medical Products Administration (NMPA) approved drug instructions within 2 weeks of starting treatment.
* 14 The symptoms of subjects with known central nervous system metastasis, spinal cord compression, meningeal metastasis, or leptomeningeal disease.
* 15 Vaccination history of live attenuated vaccine before 28 days of starting treatment, or planned vaccination of live attenuated vaccine during the study period.
* 16 History of severe allergy to macromolecule drugs or known components of TQB2916 injection.
* 17 Receiving any other investigational agent within 4 weeks before first dose.
* 18 According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subject or affect the completion of the study.